Capsaicin News and Research RSS Feed - Capsaicin News and Research

Scientists explore chili pepper's effect to develop new drug candidate for pain

Scientists explore chili pepper's effect to develop new drug candidate for pain

Biting into a chili pepper causes a burning spiciness that is irresistible to some, but intolerable to others. Scientists exploring the chili pepper's effect are using their findings to develop a new drug candidate for many kinds of pain, which can be caused by inflammation or other problems. [More]
Study: Spicy capsaicin can reduce risk of colorectal tumors

Study: Spicy capsaicin can reduce risk of colorectal tumors

Researchers at the University of California, San Diego School of Medicine report that dietary capsaicin - the active ingredient in chili peppers - produces chronic activation of a receptor on cells lining the intestines of mice, triggering a reaction that ultimately reduces the risk of colorectal tumors. [More]
New method to repair pain

New method to repair pain

A study published in the scientific journal Nature Neuroscience by Yves De Koninck and Robert Bonin, two researchers at Universit- Laval, reveals that it is possible to relieve pain hypersensitivity using a new method that involves rekindling pain so that it can subsequently be erased. [More]
Pain receptors may hold key to treating obesity, diabetes and improving metabolic health

Pain receptors may hold key to treating obesity, diabetes and improving metabolic health

Blocking a pain receptor in mice not only extends their lifespan, it also gives them a more youthful metabolism, including an improved insulin response that allows them to deal better with high blood sugar. [More]
Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for PLUMIAZ (diazepam) Nasal Spray for the treatment of people with epilepsy who experience cluster seizures. [More]
Researchers locate two molecules involved in perpetuating chronic pain

Researchers locate two molecules involved in perpetuating chronic pain

Setting the stage for possible advances in pain treatment, researchers at The Johns Hopkins University and the University of Maryland report they have pinpointed two molecules involved in perpetuating chronic pain in mice. The molecules, they say, also appear to have a role in the phenomenon that causes uninjured areas of the body to be more sensitive to pain when an area nearby has been hurt. [More]
New research offers fresh insights to drug designers searching for better pain treatments

New research offers fresh insights to drug designers searching for better pain treatments

In a technical tour de force, UC San Francisco scientists have determined, at near-atomic resolution, the structure of a protein that plays a central role in the perception of pain and heat. [More]
Study explains why south Asians have high susceptibility to developing type 2 diabetes

Study explains why south Asians have high susceptibility to developing type 2 diabetes

Lower amounts of brown adipose tissue (BAT, or ‘brown fat’) could help explain why south Asians—who make up a fifth of the world’s population—have an exceptionally high susceptibility to developing metabolic problems such as obesity and type 2 diabetes. [More]
Dietary change should be considered in chronic prostatitis

Dietary change should be considered in chronic prostatitis

Researchers from the USA say that physicians should consider dietary changes for patients with chronic prostatitis/chronic pelvic pain syndrome to improve symptoms. [More]
Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in the second clinical trial of Glial Growth Factor 2 (GGF2). This Phase 1b single-infusion trial in people with heart failure will assess tolerability of three dose levels of GGF2, and also includes several explorative measures of efficacy. [More]
Penn researchers determine link between personality types and hot-spice preferences

Penn researchers determine link between personality types and hot-spice preferences

Certain aspects of an individual's personality may be a determining factor in whether they like their food plain and bland or spicy and hot, according to research presented at the 2013 Institute of Food Technologists (IFT) Annual Meeting & Food Expo-. [More]
Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Acorda Therapeutics acquires two neuropathic pain management assets from NeurogesX

Acorda Therapeutics, Inc. today announced that it has acquired two neuropathic pain management assets from NeurogesX, Inc. Qutenza is approved by the U.S. Food and Drug Administration for the management of neuropathic pain associated with postherpetic neuralgia. [More]
Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain is caused by lesion or disease to the peripheral somatosensory nervous system. Nerve damage that can lead to peripheral neuropathic pain can happen as a result of a range of different diseases, medications or traumatic injuries. [More]
Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

Pre-treatments for peripheral neuropathic pain patch receive European Commision approval

The European Commission (EC) has approved expanded options for pre-treatment prior to use of QUTENZA (8% capsaicin patch). Before application the patient may now take an oral analgesic, or the treatment area may be pre-treated with a topical anaesthetic.1 The 8% capsaicin patch is the first and only licensed high concentration (8%) capsaicin cutaneous patch for the treatment of peripheral neuropathic pain in Europe. [More]
NFL funds WSU research to fix injured brains with new nerve cells

NFL funds WSU research to fix injured brains with new nerve cells

The National Football League thinks enough of the work that its charitable arm has given Krzysztof Czaja (pronounced K-shish-toff Chai-uh), a Washington State University neuroscientist, $100,000 to keep looking. [More]
HSS involving resiniferatoxin receives U.S. patent to alleviate intractable pain

HSS involving resiniferatoxin receives U.S. patent to alleviate intractable pain

The U. S. Patent and Trademark Office recently issued a patent to the U. S. Department of Health and Human Services involving resiniferatoxin, or RTX, an experimental compound that represents a potential new class of drugs to alleviate the intractable pain that can occur in people with advanced cancer, severe arthritis, and other extremely chronic conditions. [More]
Itch-specific nerve cells: an interview with Associate Professor Xinzhong Dong

Itch-specific nerve cells: an interview with Associate Professor Xinzhong Dong

Itch was actually defined by a German physician more than 350 years ago. His name was Samuel Hafenreffer. He defined itch as an unpleasant sensation that makes people want to scratch. You probably think this is a very simple definition but itch is really a very complex sensory modality. [More]
People with chronic inflammatory conditions may benefit from mindfulness meditation

People with chronic inflammatory conditions may benefit from mindfulness meditation

People suffering from chronic inflammatory conditions, such as rheumatoid arthritis, inflammatory bowel disease and asthma - in which psychological stress plays a major role - may benefit from mindfulness meditation techniques, according to a study by University of Wisconsin-Madison neuroscientists with the Center for Investigating Healthy Minds at the Waisman Center. [More]
Itch-specific nerve cells in skin discovered by John Hopkins scientists

Itch-specific nerve cells in skin discovered by John Hopkins scientists

Johns Hopkins researchers have uncovered strong evidence that mice have a specific set of nerve cells that signal itch but not pain, a finding that may settle a decades-long debate about these sensations, and, if confirmed in humans, help in developing treatments for chronic itch, including itch caused by life-saving medications. [More]
Johns Hopkins scientists uncover itch-specific nerve cells in skin

Johns Hopkins scientists uncover itch-specific nerve cells in skin

Johns Hopkins researchers have uncovered strong evidence that mice have a specific set of nerve cells that signal itch but not pain, a finding that may settle a decades-long debate about these sensations, and, if confirmed in humans, help in developing treatments for chronic itch, including itch caused by life-saving medications. [More]